Chinese A-Shares Rotation: Sell Metals and PCBs, Buy Pharma as Cyclical Surge Unwinds

The Quick Take

• Chinese A-share markets on June 23 saw limit-down selling in coloured metals and PCB stocks after a cyclical momentum surge left high-valuation exposures vulnerable to profit-taking.
• Capital rotated into pharmaceuticals and healthcare stocks, which offer lower valuations and earnings stability as a defensive anchor during cyclical consolidation.
• Analysts from 上市公司观察 advise avoiding high-valuation momentum cyclicals and concentrating on undervalued recovery names with sound fundamentals to weather the rotation.

June 23 produced a clear bifurcation in the Chinese A-share market's daily limit-board composition. The limit-down board was dominated by coloured metals (有色金属) stocks — including copper and zinc producers — and PCB manufacturers that had surged on AI hardware and data-centre demand narratives in prior sessions. The limit-up board, by contrast, featured pharmaceutical and healthcare names, which had lagged the cyclical rally and now attracted rotation inflows as investors sought valuation safety. This pattern — high-level theme retreat, low-level undervalued rotation — is a recognisable A-share market cycle feature where late-stage momentum positions unwind and early-stage recovery positions accumulate simultaneously within a single session.

The sector rotation carries direct earnings implications for listed Chinese companies. Coloured metals producers that rode the commodity price surge face margin compression risk if the rotation triggers further selling and commodity benchmarks soften alongside A-share prices. PCB manufacturers — which had been beneficiaries of AI server buildout demand — face valuation normalisation as the market derisks high-multiple tech supply-chain names. Pharmaceutical stocks gain a temporary re-rating premium as defensive characteristics attract capital: lower P/E ratios relative to cyclicals, cleaner balance sheets, and policy support from China's ongoing healthcare investment programme all make the sector an attractive rotation destination in a high-uncertainty market environment.

The definitive signal to watch is the A-share market's net sector fund flow data from the China Securities Finance Corporation, which tracks institutional versus retail rotation patterns. Sustained institutional buying in pharma and sustained institutional selling in metals would validate the rotation thesis as structurally driven rather than tactical one-day positioning. The macro variable is China's official PMI data and industrial output figures: an acceleration in manufacturing activity would revalidate the cyclical thesis and trigger a re-entry wave in metals and industrial commodities, reversing the current rotation. Any stimulus announcement from the National People's Congress targeting specific sectors could also disrupt the rotation dynamic, making policy monitoring equally important as sector-level data.

Synthesized from 2 sources.